CorMedix agreed to acquire substantially all Heron Therapeutics assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, in a cash and stock transaction. Closing is expected in the first quarter of 2027, subject to stockholder approval, regulatory clearance and other customary conditions.
HRTX · Heron Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“If the payment of the debt is accelerated, absent any additional funding, cash flows from our operations will be insufficient to repay such debt in full. Therefore, if all outstanding amounts under the Working Capital Facility Agreement are accelerated, management expects there will be substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $0.26
- Open
- $0.27
- Day range
- $0.25–0.28
- 52-week closing range
- $0.26–1.49
- Average volume, 30 days
- 7.2M
- Short interest
- 34.0M · 17.9% of shares · 19.5 days
- Short volume, last session
- 34%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.
Heron Therapeutics, Inc. agreed on November 8, 2026 to sell substantially all assets to CorMedix Inc. for $145.0 million cash and 14,583,333 CorMedix shares, plus royalties and contingent earn-out payments, subject to stockholder and regulatory approvals.
Heron Therapeutics and CorMedix Therapeutics entered a definitive agreement for CorMedix to acquire substantially all of its assets, subject to stockholder approval and customary closing conditions. Q3 2026 net revenue was $35.3 million, versus $38.2 million in Q3 2025.
On November 8, 2026, Heron Therapeutics agreed to sell substantially all assets to CorMedix for $145.0 million cash, subject to closing-cash and net-working-capital adjustments, plus 14,583,333 CorMedix shares, subject to stockholder approval.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. Heron reported Q2 net revenue of $37.7 million with strong acute care growth (ZYNRELEF +35% and APONVIE +74% year-over-year), but withdrew its full-year 2026 guidance following a June court decision on CINVANTI patents that threatens potential generic entry. The company reset its Hercules credit facility, reducing principal by up to $17.5 million and resetting covenants through 2027, and is evaluating strategic alternatives.
- + Acute care franchise delivered $15.3 million, up 43.9% year-over-year
- + ZYNRELEF net revenue grew 35% year-over-year to $11.1 million
- + APONVIE net revenue grew 74% year-over-year to $4.2 million with 23% NK1 segment share
- + Hercules credit facility amended with covenants reset through 2027 and up to $17.5 million principal reduction
- + Adjusted EBITDA improved to $3.2 million from $2.2 million year-over-year
- − Withdrew full-year 2026 guidance of $173-183 million net product sales and $10-20 million adjusted EBITDA
- − CINVANTI declined 9.7% year-over-year to $21.8 million due to branded competition and faces potential generic entry
- − ZYNRELEF Q2 performance came in below company expectations
- − Net loss widened to $5.5 million from $2.4 million year-over-year
- − Pro forma cash falls to approximately $24.3 million after September payment from $42.7 million
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Acute Care Net Product Sales | $15.13M | the three months ended September 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | 6.22M | nine months ended September 30, 2026 | — |
|
|
|||
| APONVIE net revenue | $12.2M | nine months ended September 30, 2026 | — |
|
|
|||
| CINVANTI net revenue | $62.3M | nine months ended September 30, 2026 | — |
| Customer A | 38% | the three months ended September 30, 2026 filing | — |
| Customer B | 32.8% | the three months ended September 30, 2026 filing | — |
| Customer C | 26.6% | the three months ended September 30, 2026 filing | — |
| Oncology Net Product Sales | $20.12M | the three months ended September 30, 2026 filing | — |
| SUSTOL net product sales | 152K | the three months ended September 30, 2026 filing | — |
| ZYNRELEF net revenue | $31.9M | nine months ended September 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HRTX
this stock
Heron Therapeutics, Inc.
|
$50.25M | -79.7% | +7.4% | — | 17.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Amount
- $1.0K–$15.0K
- Traded
- Mar 31, 2021
- Filed
- Nov 9, 2026
- This year
- 23
Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HRTX | -19.0% | -10.8% | -68.2% | -4.9% | -79.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -13.5% | -4.6% | -62.6% | +0.4% | -84.7% |